Metvix Daylight PDT in Actinic Keratosis

Observational Study to Evaluate Clinical Practice and Satisfaction With Metvix® Daylight Photodynamic Therapy (PDT) in the Treatment of Mild and/or Moderate Actinic Keratosis of the Face and/or the Scalp

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02674048

Acronym

SESAME

Enrollment

406

Registered

2016-02-04

Start date

2015-09-30

Completion date

2016-11-30

Last updated

2021-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actinic Keratosis

Brief summary

Prospective non-interventional study conducted in Australia, Brazil, Mexico and Europe to evaluate clinical practice with Metvix Daylight PDT in the treatment of mild to moderate actinic keratosis of the face/scalp and to assess physician and patient satisfaction.

Interventions

OTHERMetvix

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients to whom Metvix® Daylight-PDT has already been prescribed by their physician, according to the local label;

Design outcomes

Primary

Measure	Time frame
Percentage of physician satisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question Overall are you satisfied with Metvix DL-PDT?	3 months
Percentage of patient satisfisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question Overall, how satisfied are you with this treatment?.	3 months

Countries

Australia, France, Italy, Netherlands, Spain, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026